GlassScriptPhysician profile
Jason O Hall
NPI 1356313878
$3,425.05
in general payments reported to CMS, 2019-2025
31 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $243 · 2021: $304 · 2022: $301 · 2023: $958 · 2024: $425 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $468.06 | 2019-2025 | |
| Edwards Lifesciences Corporation | $338.81 | 2023-2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.63 | 2022-2025 | Jardiance |
| Pfizer INC. | $257.35 | 2019-2025 | |
| Boston Scientific Corporation | $248.59 | 2019-2024 | Watchman Access System, Watchman Flx, Watchman |
| Janssen Pharmaceuticals, INC | $243.58 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $228.89 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $227.49 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $150.03 | 2019-2022 | |
| Medtronic, INC. | $112.11 | 2025 | Linq II |
| Alnylam Pharmaceuticals INC. | $87.61 | 2023-2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $70.92 | 2019-2023 | |
| Cvrx, INC. | $66.12 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $64.54 | 2022 | |
| Abbott Laboratories | $64.45 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.38 | 2021-2023 | Verquvo |
| Allergan, INC. | $51.36 | 2020 | |
| Esperion Therapeutics, INC. | $47.09 | 2021-2025 | Nexletol |
| Atricure, INC. | $43.53 | 2024 | |
| Abiomed | $41.89 | 2024 | Impella |
| Impulse Dynamics (USA) INC. | $31.80 | 2023 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $31.25 | 2021-2024 | Livalo |
| Astrazeneca Pharmaceuticals LP | $29.91 | 2019-2024 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $27.86 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $25.66 | 2024 | |
| Scpharmaceuticals INC. | $21.38 | 2024 | |
| Althera Pharmaceuticals LLC | $16.78 | 2021 | |
| Tepha INC | $16.38 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.40 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $13.20 | 2024 | Edarbi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.